NCT01329289

SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma

Phase II Study of SOM230 LAR in Combination With Bortezomib and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: University of Pittsburgh · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if adding SOM230 LAR to bortezomib and dexamethasone is better than bortezomib and dexamethasone alone and if it should be investigated further.

Conditions

• Multiple Myeloma in Relapse
• Multiple Myeloma

Interventions

Type	Name	Description
DRUG	SOM230	60 mg intramuscularly (IM) on day 1 of each 28 day cycle
DRUG	Bortezomib	1.3 mg/m2 intravenously (IV) on days 1, 4, 8, and 11 of each cycle. Bortezomib will be infused by IV push.
DRUG	Dexamethasone	20 mg orally on day of and day after bortezomib (Days 1, 2, 4, 5, 8, 9, 11, 12).

Timeline

• Start date: 2011-12-01
• Primary completion: 2012-02-01
• Completion: 2012-02-01
• First posted: 2011-04-05
• Last updated: 2016-02-12

Locations

1 site across 1 country: United States